Henry Ford Cancer Institute is First in the World to Activate Two New Treatments in GBM AGILE Trial for Glioblastoma Brain Cancer February 3, 2021 • 5:15 PM EST
Kintara Announces Initiation of Patient Recruitment for VAL-083's Study Arm in the GBM AGILE Trial January 13, 2021 • 8:00 AM EST
Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazia’s Paxalisib and Kintara’s VAL-083 in GBM AGILE Trial January 6, 2021 • 1:00 PM EST
Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference January 5, 2021 • 8:00 AM EST
Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit December 3, 2020 • 8:30 AM EST
Kintara Therapeutics Reports 10 Months Progression-Free Survival in Newly-Diagnosed MGMT-unmethylated GBM from Ongoing MD Anderson Cancer Center Phase 2 Study November 19, 2020 • 8:00 AM EST
Kintara Therapeutics Announces First Fiscal Quarter 2021 Financial Results and Recent Corporate Updates November 13, 2020 • 8:00 AM EST
Kintara and the Global Coalition for Adaptive Research Execute Agreement for VAL-083's Participation in the GBM AGILE Registrational Study October 21, 2020 • 8:00 AM EDT
Kintara Therapeutics Announces Fiscal Year 2020 Financial Results and Recent Corporate Updates September 21, 2020 • 8:30 AM EDT
Kintara Therapeutics Completes Final Closing of Previously Announced Private Placement For an Aggregate of $25 Million September 1, 2020 • 8:30 AM EDT